Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Cash-to-Debt : 4.29 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Chongqing Genrix Biopharmaceutical Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 4.29.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Chongqing Genrix Biopharmaceutical Co could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Chongqing Genrix Biopharmaceutical Co's Cash-to-Debt or its related term are showing as below:

SHSE:688443' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09 Med: 0.68 Max: 4.75
Current: 4.29

During the past 5 years, Chongqing Genrix Biopharmaceutical Co's highest Cash to Debt Ratio was 4.75. The lowest was 0.09. And the median was 0.68.

SHSE:688443's Cash-to-Debt is ranked worse than
55.82% of 1521 companies
in the Biotechnology industry
Industry Median: 6.39 vs SHSE:688443: 4.29

Chongqing Genrix Biopharmaceutical Co Cash-to-Debt Historical Data

The historical data trend for Chongqing Genrix Biopharmaceutical Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Chongqing Genrix Biopharmaceutical Co Cash-to-Debt Chart

Chongqing Genrix Biopharmaceutical Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.09

0.16

0.77

0.36

4.56

Chongqing Genrix Biopharmaceutical Co Quarterly Data
	Dec19	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial								0.24	3.85	4.75	4.56	4.29

Competitive Comparison of Chongqing Genrix Biopharmaceutical Co's Cash-to-Debt

For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chongqing Genrix Biopharmaceutical Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chongqing Genrix Biopharmaceutical Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Chongqing Genrix Biopharmaceutical Co's Cash-to-Debt falls into.

Chongqing Genrix Biopharmaceutical Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Chongqing Genrix Biopharmaceutical Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2919.845	/	(10.696	+	630.296)
	=	4.56

Chongqing Genrix Biopharmaceutical Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2758.128	/	(12.169	+	630.12)
	=	4.29

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Chongqing Genrix Biopharmaceutical Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338

Website

http://www.genrixbio.com

Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.

Executives

Jiang Ren Sheng

Director

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Headlines

No Headlines